Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

Part of paid clinical trials in Saint Charles, Missouri.

Sponsor
Lindenwood University
Study ID
NCT06672952
Status
Recruiting
Apply to this trial

Conditions

  • Blood Flow
  • Cognitive Function
  • Endurance Exercise
  • Exercise Performance
  • Exercise Recovery
  • Nitric Oxide

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Accepted

Interventions

  • 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation — DIETARY_SUPPLEMENT
    The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.
  • Placebo — DIETARY_SUPPLEMENT
    The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.
  • 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation — DIETARY_SUPPLEMENT
    The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.

Study Details

The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.

Key Dates

Start date
Apr 15, 2025
Status verified
Dec 2025
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo
    Participants in this arm will receive a placebo supplement consisting of 400 mg of cellulose per day. The placebo is designed to match the appearance and dosage form of the active interventions, allowing for blinding in the study.
  • Experimental: 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
    Participants in this arm will receive a total of 200 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day, along with an additional 200 mg of cellulose. This will provide a daily dosage of 400 mg, maintaining blinding to ensure the placebo effect is accounted for.
  • Experimental: 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
    Participants in this arm will receive a total of 400 mg of glucosyl-hesperidin (CITRAPEAK®) supplementation per day. This higher dose is intended to evaluate its effects on exercise performance, recovery, and cognitive function compared to the placebo and lower dose.

Primary Outcome Measure

Change from Baseline in Peak VO2 at Week 8 Following Glucosyl-Hesperidin (CITRAPEAK) Supplementation [ Time Frame: Baseline and Week 8 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Lindenwood UniversitySaint CharlesMissouri63301
Anthony M Hagele, MS
[email protected]
636-949-4785
Chad M Kerksick, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Saint Charles, MO

By research site
Lindenwood University· Saint Charles, MO

Related Studies